The most significant advance in HIF pathway targeting strategies came in recent months with The United States Food and Drug Administration (FDA) approval of the HIF2α inhibitor Belzutifan for the treatment of von Hippel-Lindau associated tumours including renal cell carcinomas, central nervous system haemangiomas and pancreatic neuroendocrine tumours. The gene discussed is EPAS1; the disease is neoplasm.